- Home
- ANAB vs GENI Comparison
ANAB vs GENI Comparison
Compare ANAB & GENI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | GENI |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANAB | GENI |
|---|---|---|
| Price | $63.70 | $4.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | ★ $71.67 | $12.75 |
| AVG Volume (30 Days) | 567.5K | ★ 4.4M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $234,603,000.00 | N/A |
| Revenue This Year | N/A | $24.00 |
| Revenue Next Year | $52.14 | $20.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $17.11 | $3.83 |
| 52 Week High | $73.30 | $13.73 |
Technical Indicators
Market Signals| Indicator | ANAB | GENI |
|---|---|---|
| Relative Strength Index (RSI) | 51.98 | 39.28 |
| Support Level | $53.46 | $3.83 |
| Resistance Level | $69.56 | $5.05 |
| Average True Range (ATR) | 5.32 | 0.26 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 64.47 | 32.24 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas including Sports Technology and Services; Betting Technology, Content and Services; and Media Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content and Services division. Geographically, the company derives a majority of its revenue from Europe.